Induced Pluripotent Stem Cells-based Therapy Development
Creative Biolabs is an industry leader in data validation for stem cell therapy projects. Our highly skilled scientists work with customers to develop client-specific custom protocols. We provide state-of-the-art data validation services to meet every unique need in your stem cell research project.
Induced Pluripotent Stem Cells (iPSCs)
iPSCs are a type of pluripotent stem cells that can be reprogrammed from adult somatic cells in healthy or diseased patients. These pluripotent stem cells have the ability to propagate indefinitely and to differentiate into any type of cell in the body, which makes them a valuable tool for the potential design of cell therapy protocols. iPSCs can be obtained through the reprogramming of an individual's somatic stem cells. Reprogramming of human somatic cells can be induced by the following methods: 1) viral transfection of Oct4, Sox2, c-Myc, Klf4, Nanog and Lin28 genes; 2) non-viral methods using a nonintegrating episomal vector derived from Epstein-Barr virus, plasmid vectors or piggyBac transposon/transposase systems; 3) direct delivery of the reprogramming proteins (piPSCs) and signal transduction inhibitors and chemical promoters (Fig.1).
Fig.1 Generation of induced pluripotent stem cells for use in cell therapy. (Liras, 2013)
The ability of stem cells to proliferate indefinitely and differentiate into any cell type in adults makes them important applications in tissue engineering, regenerative medicine, cell therapy, and gene therapy. For example, researchers are developing iPSCs as therapies for replacing damaged cells or reintroducing healthy copies of genes in people with genetic diseases. Moreover, iPSCs can also be used in the treatment of organ-specific diseases such as diabetes, liver and cardiovascular diseases, immunological disorders and monogenic hereditary diseases such as hemophilia.
Compared with other treatment methods, iPSCs therapy shows several obvious advantages. iPSCs technology allows the development of patient-specific cell therapy protocols as they are genetically identical to the donor and thus preventing the occurrence of immune rejection in autologous transplantations. Furthermore, unlike embryonic stem cells, iPSCs are not associated with any ethical controversy, so the regulatory conditions governing iPSCs are much less stringent. Lastly, iPSCs are very similar to embryonic stem cells in terms of molecular and functional properties.
iPSCs Service at Creative Biolabs
Creative Biolabs has a talent pool of dedicated data professionals who can provide data verification/validation services to enhance your existing sets. Our validation services cover all stages of stem cell therapy development, from stem cell isolation, stem cell function assay to safety and efficacy assessment. Our experts use the most advanced technology and tools to scrutinize your data and implement proven methods to authenticate your records and ensure they are accurate, consistent and up-to-date. In addition, we also provide project management and one-on-one client consulting services to help research groups complete iPSC therapy projects quickly and efficiently.
Responsible. Simplified project management-based approach with special emphasis on getting projects started quickly and completing projects on time.
Collaboration. Our multidisciplinary team of experts has the expertise and flexibility to meet your unique needs in a collaborative way.
Expertise. We have an advanced platform and more than 10 years of experience in stem cell research.
Quality. We provide comprehensive, high-quality data validation services and customized solutions to achieve the highest customer satisfaction.
We are your premier partner for accelerating the progress of the project. Our iPSCs services can be tailored to meet your project requirements, helping you to save time and money. Please feel free to contact us for further information or requests.
Liras, A.; et al. Induced Pluripotent Stem Cells: Therapeutic Applications in Monogenic and Metabolic Diseases, and Regulatory and Bioethical considerations. 2013.